Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Core Insights - Indaptus Therapeutics, a clinical stage biotechnology company, is focused on innovative treatments for cancer and viral infections, and will present at the 3rd Donor Selection & Cell Source Summit in San Diego [1][4] Company Overview - Indaptus Therapeutics is leveraging over a century of immunotherapy advancements, utilizing a patented Decoy platform that activates both innate and adaptive immune responses through a multi-targeted approach [5] - The Decoy platform consists of non-pathogenic, Gram-negative bacteria designed to activate immune pathways safely via intravenous administration, showing promise in treating various cancers and viral infections [5] Research and Development - Dr. Michael Newman will present research on the Decoy bacterial platform, which aims to address donor cell variability in allogeneic immune cell cancer therapy [2][4] - The lead candidate, Decoy20, utilizes killed bacteria to induce a broad immune response, potentially enhancing the quality and consistency of allogeneic immune cell products [3][4] - Preclinical data indicates that Decoy bacteria can activate key immune cell types, suggesting their potential to improve the potency and reproducibility of donor-derived cell therapies [4] Industry Context - The Donor Selection & Cell Source Summit aims to tackle challenges in donor screening and cell sourcing within the expanding allogeneic cell therapy market, bringing together industry and academic leaders [4]